Doximity price target raised to $65 from $55 at Mizuho

Mizuho raised the firm’s price target on Doximity (DOCS) to $65 from $55 and keeps a Neutral rating on the shares. The company reported its third consecutive “beat and raise” quarter as it continues to increase engagement with physicians on its app, the analyst tells investors in a research note. The firm believes Doximity’s new pharma client portal, which allows clients to more easily track marketing spend virtually real-time, is another key factor in accelerating revenue growth.